Loading...

NRx Pharmaceuticals, Inc.

NRXP•NASDAQ
HealthcareBiotechnology
$2.62
$-0.07(-2.60%)

NRx Pharmaceuticals, Inc. (NRXP) Stock Overview

Explore NRx Pharmaceuticals, Inc.’s financial performance, market position, analyst ratings, and future outlook.

Revenue Growth
0.00%
Profit Growth
$-1.47
↑ 16.66%
EPS Growth
$-1.47
↑ 39.95%
Operating Margin
-408775.00%
↑ 32.93%
ROE
112.67%
↑ 16.66%
Dividend Yield
0.00%

Analyst Recommendations

Strong Buy
0
Buy
2
Hold
0
Sell
0
Strong Sell
0

Price Targets

Low$0.00
Average$0.00
High$0.00

Company Profile

NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.

CEO

Dr. Jonathan C. Javitt M.D., M.P.H.

Employees

2

Headquarters

1201 Orange Street, Wilmington, DE

Founded

2017

Frequently Asked Questions

Meyka LogoMeyka

Meyka is the best Alternative Data platform powered by AI providing research insights for investors

Connect With Us

Legal

Resources

Market

Legal Disclaimer

The information provided by Meyka AI PTY LTD is for informational and research purposes only and does not constitute financial, investment, or trading advice. Meyka is a research platform, not a financial advisory service. Investing in financial markets involves risks, and past performance does not guarantee future results. Users should conduct their own due diligence, consult with professional financial advisors, and assess their risk tolerance before making investment decisions. Meyka and its operators are not liable for any financial losses incurred from the use of information on this platform. The data provided is derived from publicly available sources and is believed to be reliable but may not always be accurate or up to date. Users should independently verify information and not rely solely on Meyka for financial decisions. By using Meyka, you acknowledge that it does not provide financial advice or recommendations and agree to seek guidance from a qualified financial professional before making any investment decisions.

© 2025 Meyka AI PTY LTD. All rights reserved.